Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-tenatoprazole
- Development stage
- Phase 2
- Lead developer
- Mitsubishi Tanabe Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**S-tenatoprazole** is the S-enantiomer of tenatoprazole, a proton pump inhibitor (PPI) of the imidazopyridine class, developed as a small molecule drug for the treatment of acid-related gastrointestinal disorders. It inhibits the gastric H+,K+-ATPase (proton pump) in the parietal cells of the stomach, thereby suppressing gastric acid secretion. S-tenatoprazole exhibits a prolonged plasma half-life compared to other PPIs, and compared to the R-enantiomer or racemic tenatoprazole, it is metabolized more slowly (notably by CYP3A4), resulting in more uniform and extended gastric acid suppression, especially beneficial for nocturnal acid control. It is being investigated primarily for gastroesophageal reflux disease (GERD), peptic ulcers, and related indications, but has also been considered for potential anti-cancer and anti-viral applications.
- Brand names
- S-Tenatoprazole-Na
- Other names
- S-tenatoprazole sodium
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on S-tenatoprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S-tenatoprazole.